The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Polypeptide Drug Market Research Report 2024
Synopsis
Polypeptide antibiotic. Polypeptide antibiotics are a chemically diverse class of anti-infective and antitumor antibiotics containing non-protein polypeptide chains. Examples of this class include actinomycin, bacitracin, colistin, and polymyxin B. Actinomycin-D has found use in cancer chemotherapy.
The global Polypeptide Drug market was valued at US$ 689 million in 2023 and is anticipated to reach US$ 1037.4 million by 2030, witnessing a CAGR of 6.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Polypeptide Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polypeptide Drug.
Report Scope
The Polypeptide Drug market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Polypeptide Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Polypeptide Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck Serono
Ferring Pharmaceuticals
Ipsen PHarma Biotech
Lilly
Asahi Kasei
AstraZeneca
SciClone Pharmaceuticals
Takeda
Roche
Sanofi
Segment by Type
Injection
Nasal Administration
Lung Administration
Oral Administration
Transdermal Administration
Segment by Application
Immunity Regulating Medicine (Allergy Infection and Immune)
Digestive System Drugs (Gastrointestinal Type)
Bone and Connective Tissue Types (Thyroid hormones Drug)
Gynecologic or Obstetric Drug
Tumor Drug
Urinary System Drug
Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Polypeptide Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Polypeptide Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Polypeptide antibiotic. Polypeptide antibiotics are a chemically diverse class of anti-infective and antitumor antibiotics containing non-protein polypeptide chains. Examples of this class include actinomycin, bacitracin, colistin, and polymyxin B. Actinomycin-D has found use in cancer chemotherapy.
The global Polypeptide Drug market was valued at US$ 689 million in 2023 and is anticipated to reach US$ 1037.4 million by 2030, witnessing a CAGR of 6.4% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Polypeptide Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Polypeptide Drug.
Report Scope
The Polypeptide Drug market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Polypeptide Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Polypeptide Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Merck Serono
Ferring Pharmaceuticals
Ipsen PHarma Biotech
Lilly
Asahi Kasei
AstraZeneca
SciClone Pharmaceuticals
Takeda
Roche
Sanofi
Segment by Type
Injection
Nasal Administration
Lung Administration
Oral Administration
Transdermal Administration
Segment by Application
Immunity Regulating Medicine (Allergy Infection and Immune)
Digestive System Drugs (Gastrointestinal Type)
Bone and Connective Tissue Types (Thyroid hormones Drug)
Gynecologic or Obstetric Drug
Tumor Drug
Urinary System Drug
Metabolic Drug (Insulin and Other Hypoglycemic Agents)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Polypeptide Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Polypeptide Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Polypeptide Drug Market Overview
1.1 Product Overview and Scope of Polypeptide Drug
1.2 Polypeptide Drug Segment by Type
1.2.1 Global Polypeptide Drug Market Value Comparison by Type (2024-2030)
1.2.2 Injection
1.2.3 Nasal Administration
1.2.4 Lung Administration
1.2.5 Oral Administration
1.2.6 Transdermal Administration
1.3 Polypeptide Drug Segment by Application
1.3.1 Global Polypeptide Drug Market Value by Application: (2024-2030)
1.3.2 Immunity Regulating Medicine (Allergy Infection and Immune)
1.3.3 Digestive System Drugs (Gastrointestinal Type)
1.3.4 Bone and Connective Tissue Types (Thyroid hormones Drug)
1.3.5 Gynecologic or Obstetric Drug
1.3.6 Tumor Drug
1.3.7 Urinary System Drug
1.3.8 Metabolic Drug (Insulin and Other Hypoglycemic Agents)
1.4 Global Polypeptide Drug Market Size Estimates and Forecasts
1.4.1 Global Polypeptide Drug Revenue 2019-2030
1.4.2 Global Polypeptide Drug Sales 2019-2030
1.4.3 Global Polypeptide Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Polypeptide Drug Market Competition by Manufacturers
2.1 Global Polypeptide Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Polypeptide Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Polypeptide Drug Average Price by Manufacturers (2019-2024)
2.4 Global Polypeptide Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Polypeptide Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Polypeptide Drug, Product Type & Application
2.7 Polypeptide Drug Market Competitive Situation and Trends
2.7.1 Polypeptide Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Polypeptide Drug Players Market Share by Revenue
2.7.3 Global Polypeptide Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Polypeptide Drug Retrospective Market Scenario by Region
3.1 Global Polypeptide Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Polypeptide Drug Global Polypeptide Drug Sales by Region: 2019-2030
3.2.1 Global Polypeptide Drug Sales by Region: 2019-2024
3.2.2 Global Polypeptide Drug Sales by Region: 2025-2030
3.3 Global Polypeptide Drug Global Polypeptide Drug Revenue by Region: 2019-2030
3.3.1 Global Polypeptide Drug Revenue by Region: 2019-2024
3.3.2 Global Polypeptide Drug Revenue by Region: 2025-2030
3.4 North America Polypeptide Drug Market Facts & Figures by Country
3.4.1 North America Polypeptide Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Polypeptide Drug Sales by Country (2019-2030)
3.4.3 North America Polypeptide Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Polypeptide Drug Market Facts & Figures by Country
3.5.1 Europe Polypeptide Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Polypeptide Drug Sales by Country (2019-2030)
3.5.3 Europe Polypeptide Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Polypeptide Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Polypeptide Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Polypeptide Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Polypeptide Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Polypeptide Drug Market Facts & Figures by Country
3.7.1 Latin America Polypeptide Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Polypeptide Drug Sales by Country (2019-2030)
3.7.3 Latin America Polypeptide Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Polypeptide Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Polypeptide Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Polypeptide Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Polypeptide Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Polypeptide Drug Sales by Type (2019-2030)
4.1.1 Global Polypeptide Drug Sales by Type (2019-2024)
4.1.2 Global Polypeptide Drug Sales by Type (2025-2030)
4.1.3 Global Polypeptide Drug Sales Market Share by Type (2019-2030)
4.2 Global Polypeptide Drug Revenue by Type (2019-2030)
4.2.1 Global Polypeptide Drug Revenue by Type (2019-2024)
4.2.2 Global Polypeptide Drug Revenue by Type (2025-2030)
4.2.3 Global Polypeptide Drug Revenue Market Share by Type (2019-2030)
4.3 Global Polypeptide Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Polypeptide Drug Sales by Application (2019-2030)
5.1.1 Global Polypeptide Drug Sales by Application (2019-2024)
5.1.2 Global Polypeptide Drug Sales by Application (2025-2030)
5.1.3 Global Polypeptide Drug Sales Market Share by Application (2019-2030)
5.2 Global Polypeptide Drug Revenue by Application (2019-2030)
5.2.1 Global Polypeptide Drug Revenue by Application (2019-2024)
5.2.2 Global Polypeptide Drug Revenue by Application (2025-2030)
5.2.3 Global Polypeptide Drug Revenue Market Share by Application (2019-2030)
5.3 Global Polypeptide Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Polypeptide Drug Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Merck Serono
6.2.1 Merck Serono Corporation Information
6.2.2 Merck Serono Description and Business Overview
6.2.3 Merck Serono Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Serono Polypeptide Drug Product Portfolio
6.2.5 Merck Serono Recent Developments/Updates
6.3 Ferring Pharmaceuticals
6.3.1 Ferring Pharmaceuticals Corporation Information
6.3.2 Ferring Pharmaceuticals Description and Business Overview
6.3.3 Ferring Pharmaceuticals Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Ferring Pharmaceuticals Polypeptide Drug Product Portfolio
6.3.5 Ferring Pharmaceuticals Recent Developments/Updates
6.4 Ipsen PHarma Biotech
6.4.1 Ipsen PHarma Biotech Corporation Information
6.4.2 Ipsen PHarma Biotech Description and Business Overview
6.4.3 Ipsen PHarma Biotech Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ipsen PHarma Biotech Polypeptide Drug Product Portfolio
6.4.5 Ipsen PHarma Biotech Recent Developments/Updates
6.5 Lilly
6.5.1 Lilly Corporation Information
6.5.2 Lilly Description and Business Overview
6.5.3 Lilly Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Lilly Polypeptide Drug Product Portfolio
6.5.5 Lilly Recent Developments/Updates
6.6 Asahi Kasei
6.6.1 Asahi Kasei Corporation Information
6.6.2 Asahi Kasei Description and Business Overview
6.6.3 Asahi Kasei Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Asahi Kasei Polypeptide Drug Product Portfolio
6.6.5 Asahi Kasei Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 AstraZeneca Polypeptide Drug Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 SciClone Pharmaceuticals
6.8.1 SciClone Pharmaceuticals Corporation Information
6.8.2 SciClone Pharmaceuticals Description and Business Overview
6.8.3 SciClone Pharmaceuticals Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 SciClone Pharmaceuticals Polypeptide Drug Product Portfolio
6.8.5 SciClone Pharmaceuticals Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Corporation Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Takeda Polypeptide Drug Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 Roche
6.10.1 Roche Corporation Information
6.10.2 Roche Description and Business Overview
6.10.3 Roche Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Roche Polypeptide Drug Product Portfolio
6.10.5 Roche Recent Developments/Updates
6.11 Sanofi
6.11.1 Sanofi Corporation Information
6.11.2 Sanofi Polypeptide Drug Description and Business Overview
6.11.3 Sanofi Polypeptide Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Sanofi Polypeptide Drug Product Portfolio
6.11.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Polypeptide Drug Industry Chain Analysis
7.2 Polypeptide Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Polypeptide Drug Production Mode & Process
7.4 Polypeptide Drug Sales and Marketing
7.4.1 Polypeptide Drug Sales Channels
7.4.2 Polypeptide Drug Distributors
7.5 Polypeptide Drug Customers
8 Polypeptide Drug Market Dynamics
8.1 Polypeptide Drug Industry Trends
8.2 Polypeptide Drug Market Drivers
8.3 Polypeptide Drug Market Challenges
8.4 Polypeptide Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
